Artios Pharma Launch to Focus on Novel DDR Cancer Therapies
DNA Damage Response is a mechanism through which cells repair their damaged DNA. Research has shown that tumours manipulate this ability to repair DNA, allowing them to mutate and evolve. Targeting a tumour's remaining DNA repair mechanisms has been proven, through the recent clinical successes of PARP inhibitors and the launch of Lynparza™ (olaparib; AstraZeneca), to cause its selective death, a concept known as "synthetic lethality."
Artios is led by Chief Executive Officer Dr. Niall Martin, who has proven expertise in DDR drug discovery, having previously worked as Director of Drug Discovery at KuDOS Pharmaceuticals (sold to AstraZeneca in January 2006 for $210m) where he established the drug-screening capabilities that underpinned many KuDOS drug discovery programmes in DNA repair. Most notably, Dr. Martin was project leader on KuDOS' PARP inhibitor programme and played a key role in identifying Lynparza™ (olaparib) along with other DDR inhibitors. Prior to joining Artios, Dr. Martin was a co-founder and served as Chief Operating Officer at MISSION Therapeutics, a company focussed on researching and drugging the ubiquitin pathways for the treatment of cancers and other diseases.
Artios is actively building a pipeline of highly promising first-in-class DDR therapies identified from a global network of leading researchers in the DDR field. The Company announces today that it has in-licensed two programmes against novel targets, Pol-theta and a second target, as yet undisclosed, from Cancer Research Technology (CRT), the development and commercialisation arm of Cancer Research UK. Both programmes are in the drug discovery phase, and represent exciting opportunities to modulate the DNA repair processes in certain tumours leading to synthetic lethality.
In addition, Artios also announces today that it has entered into a research collaboration with CRT, to further access its world-class research on DDR targets in drug discovery. Under the terms of the agreement, Artios will work with CRT to discover and develop drugs against several new DDR targets over the next few years.
Commenting on the launch of Artios Pharma, Dr. Niall Martin, Chief Executive Officer, said: "Targeting the DNA Damage Response is an exciting and promising field of biology with growing interest following the recent success of PARP inhibitors. DDR drug products have the potential to become established first-line treatments, either as single agents or for use in combination with many currently approved therapies. It is an ideal time for Artios to be entering the field as a DDR focussed, independent biotech company and we are delighted to welcome our world-class investors to the Company and to announce our first partnership with Cancer Research Technology."
On behalf of the investors, Kate Bingham, Managing Partner at SV Life Sciences said: "Artios represents a unique opportunity to build a world-class DDR pipeline through partnerships with leading DNA repair researchers in the UK and worldwide. We are delighted with the strong investor interest in Artios, reflecting the potential of DDR. I am pleased to say that this is one of the most sought after and over-subscribed investment opportunities we have recently put together."
Dr. Keith Blundy, CRT's Chief Executive Officer, said: "We are pleased to have worked with SV Life Sciences to bring together the Cancer Research UK academic network, a portfolio of leading DNA damage response opportunities and the CRT Discovery Laboratories' drug discovery platform to help build a strong development pipeline for Artios. This exciting development has enabled us to leverage the expertise of the Artios management team and financing from leading venture companies to help establish a company that has the potential to bring real impact to cancer patients."
Комментарии